Scope
The joint AAD–NPF guidance covers topical treatment of psoriasis, clinical severity assessment and the evidence for complementary approaches. These official highlights support practical treatment selection but do not reproduce the complete prescribing recommendations.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Choosing and combining topical treatment
- Topical corticosteroids are recommended for plaque psoriasis outside intertriginous areas. Treatment beyond 12 weeks may be considered with careful physician supervision. [1]
- Vitamin D analogues, tazarotene and calcineurin inhibitors can be used alone or with corticosteroids as steroid-sparing options. Alternating steroid and steroid-sparing treatment has an important role in chronic management. [1]
- Emollients, salicylic acid, anthralin and coal tar are additional topical options, either alone or combined with topical corticosteroids. [1]
- Topical treatments may accompany biologic or other systemic therapies to improve treatment efficacy. [1]
Assess severity and patient impact
- Body surface area (BSA), physician global assessment (PGA) and BSA × PGA can be used in routine practice. PASI is recommended for clinical trials rather than routine clinical practice. [1]
- Symptom and quality-of-life tools such as DLQI, PSI and pruritus assessment can provide useful information about the patient’s quality of life. [1]
Interpret complementary-treatment evidence cautiously
- The guideline does not recommend for or against the assessed complementary approaches because evidence is insufficient or conflicting. The review covers traditional Chinese medicine, specified herbal products, dietary interventions and supplements, and mind–body interventions; listing them is not an endorsement. [1]
Limitations and use
- Only the official topical-therapy and severity-assessment highlights are covered. The source does not establish specific drug strengths, application schedules or all site-specific prescribing precautions. Other psoriasis guideline sections are outside this summary.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Psoriasis: topical therapy and severity assessment — focused recommendation source
Selected recommendation material consulted
Publication details
- Issuing organisation
- AAD / NPF
- First published
- 30 July 2020
- Resource type
- Clinical practice guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.